830 related articles for article (PubMed ID: 15762770)
21. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
Neuvonen PJ; Niemi M; Backman JT
Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259
[TBL] [Abstract][Full Text] [Related]
22. MDR- and CYP3A4-mediated drug-herbal interactions.
Pal D; Mitra AK
Life Sci; 2006 Mar; 78(18):2131-45. PubMed ID: 16442130
[TBL] [Abstract][Full Text] [Related]
23. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
25. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites.
Zhao XJ; Jones DR; Wang YH; Grimm SW; Hall SD
Xenobiotica; 2002 Oct; 32(10):863-78. PubMed ID: 12419016
[TBL] [Abstract][Full Text] [Related]
26. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.
Patel J; Buddha B; Dey S; Pal D; Mitra AK
Am J Ther; 2004; 11(4):262-77. PubMed ID: 15266218
[TBL] [Abstract][Full Text] [Related]
27. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
Yamazaki H; Shimada T
Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
[TBL] [Abstract][Full Text] [Related]
28. Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions.
Chen Y; Liu L; Monshouwer M; Fretland AJ
Drug Metab Dispos; 2011 Nov; 39(11):2085-92. PubMed ID: 21835977
[TBL] [Abstract][Full Text] [Related]
29. Inhibition selectivity of grapefruit juice components on human cytochromes P450.
Tassaneeyakul W; Guo LQ; Fukuda K; Ohta T; Yamazoe Y
Arch Biochem Biophys; 2000 Jun; 378(2):356-63. PubMed ID: 10860553
[TBL] [Abstract][Full Text] [Related]
30. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.
Polasek TM; Sadagopal JS; Elliot DJ; Miners JO
Eur J Clin Pharmacol; 2010 Mar; 66(3):275-83. PubMed ID: 20012430
[TBL] [Abstract][Full Text] [Related]
31. Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants.
Akiyoshi T; Ito M; Murase S; Miyazaki M; Guengerich FP; Nakamura K; Yamamoto K; Ohtani H
Drug Metab Pharmacokinet; 2013; 28(5):411-5. PubMed ID: 23514827
[TBL] [Abstract][Full Text] [Related]
32. Mechanism-Based Inactivation of Cytochrome P450 3A4 by Benzbromarone.
Tang LWT; Verma RK; Fan H; Chan ECY
Mol Pharmacol; 2021 Apr; 99(4):266-276. PubMed ID: 33436520
[TBL] [Abstract][Full Text] [Related]
33. Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban.
Tang LWT; Wu G; Chan ECY
J Pharmacol Exp Ther; 2022 Aug; 382(2):123-134. PubMed ID: 35640957
[TBL] [Abstract][Full Text] [Related]
34. NADPH-Independent Inactivation of CYP2B6 and NADPH-Dependent Inactivation of CYP3A4/5 by PBD: Potential Implication for Assessing Covalent Modulators for Time-Dependent Inhibition.
Kosaka M; Zhang D; Wong S; Yan Z
Drug Metab Dispos; 2020 Aug; 48(8):655-661. PubMed ID: 32482757
[TBL] [Abstract][Full Text] [Related]
35. Mechanism-based inactivation of CYP3A by HIV protease inhibitors.
Ernest CS; Hall SD; Jones DR
J Pharmacol Exp Ther; 2005 Feb; 312(2):583-91. PubMed ID: 15523003
[TBL] [Abstract][Full Text] [Related]
36. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes.
Masubuchi Y; Horie T
Chem Res Toxicol; 1999 Oct; 12(10):1028-32. PubMed ID: 10525281
[TBL] [Abstract][Full Text] [Related]
37. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
Hanioka N; Ozawa S; Jinno H; Tanaka-Kagawa T; Nishimura T; Ando M; Sawada Ji J
Drug Metab Dispos; 2002 Apr; 30(4):391-6. PubMed ID: 11901092
[TBL] [Abstract][Full Text] [Related]
38. Mechanism-based inactivation of human cytochrome P450 1A2 and 3A4 isoenzymes by anti-tumor triazoloacridinone C-1305.
Potęga A; Fedejko-Kap B; Mazerska Z
Xenobiotica; 2016 Dec; 46(12):1056-1065. PubMed ID: 26928326
[TBL] [Abstract][Full Text] [Related]
39. Drug interactions with cisapride: clinical implications.
Michalets EL; Williams CR
Clin Pharmacokinet; 2000 Jul; 39(1):49-75. PubMed ID: 10926350
[TBL] [Abstract][Full Text] [Related]
40. In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions.
Filppula AM; Mustonen TM; Backman JT
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):739-748. PubMed ID: 29956478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]